Background
==========

As a relatively "new" virus, only identified in 1989 \[[@B1]\] and first cultured successfully in 2005 \[[@B2]\], there is still much that is unknown about the hepatitis C virus (HCV) and this has hindered the development of an effective vaccine. The following are some of the challenges to successful HCV vaccine design.

1\) The virus is highly mutable and exists as a quasispecies within the host and genotypes cluster geographically.

2\) Host cell responses to HCV infection are poorly defined and inconsistent among infected individuals.CD4+ and CD8+ T-cell responses are also not cross-protective to heterologous genotypes \[[@B3]\] and, to date, there is no immunodominant epitope that is consistently found in HCV-positive individuals \[[@B4]\].

3\) Humans are the only natural host of HCV, and suitable laboratory models have only been developed recently. The chimpanzee has been infected in the laboratory \[[@B5]\], but studies using this model are expensive and limited. The mouse model for viral pathogenesis studies promises a more practical and plausible alternative \[[@B6],[@B7]\].

Epitope-based vaccines promote an immune response by presenting immunogenic peptides (viral genotype-specific) bound to major histocompatibility (MHC) molecules (host specific) to the T cell receptor. Class II- proteins are presented to T helper cells by antigen presenting cells (APCs) with the aid of the CD4 co-receptor whereas class I- proteins are presented by the infected target cell to cytotoxic T cells with the aid of the CD8 co-receptor. The T helper response is important in directing and activating the immune response, including the effectiveness of CD8+ T cells \[[@B8]\].An effective vaccine must be capable of inducing and maintaining powerful CD4 and CD8 T-cell immunity in the greatest proportion of its target population.

Both HCV genotype and HLA allele frequency are distributed geographically. Viral genotype, host genetic background \[[@B9]\] and HLA class I- \[[@B10]\] and class II- alleles \[[@B11]\] are associated with both HCV disease progression and sustained response to therapy \[[@B12]\]. South Africa has diverse ethnic groups, hence a high diversity of HLA genetic background \[[@B13]\]. Black Africans, including the well-studied Zulu ethnic group, constitute the majority (79.4%) population in the country (Statistics South Africa, \[[@B14]\], <http://www.statssa.gov.za/PublicationsHTML/P03022010/html/P03022010.html>). Other major population groups include Caucasians (Europeans and Indian/Asian,11.8%) and those of mixed race (8.8%). The predominant HCV genotype in South Africa is genotype 5a. This little studied genotype accounts for 57% of the HCV infections in South Africa with the very well studied genotype 1 accounting for 23% \[[@B15]\]. In comparison, genotype 1 accounts for 70% of HCV infections in USA \[[@B16]\]. Hence, most peptide-based vaccines studies concentrate mainly on HCV genotype 1 epitopes restricted by HLA-A\*02 which is the most common HLA allele in populations of European/Caucasian descent (New allele Frequency Database \[[@B17]\], <http://www.allefrequencies.net>).

The binding of the epitope to the HLA-molecule is a highly selective process as only 1 in 40--200 peptides would bind to the HLA class I- or II- allele with high affinity to produce an efficient immune response \[[@B18]\]. Computer prediction servers have made it possible to identify potentially strong peptide binders to HLA molecules that can then be tested *in vitro* and *in vivo* as putative epitopes for peptide-based vaccines. This is a cost- and time-saving exercise as it is expensive and laborious to synthesize and test several 9-mer or overlapping peptides over long target antigens. There are various computational prediction servers available and their sensitivity is constantly improving, including more than 20 prediction servers to identify HLA-II binding peptides \[[@B19]\].

We hypothesize that putative vaccines based on restriction by the HLA-A\*02 allele and genotype 1 sequences will not perform optimally in South Africa. The aim of the study was, therefore, to investigate the heterogeneity of well studied HCV epitope sequences across HCV genotypes (with particular reference to genotype 5a) and assess their immunogenicity against prevalent local HLA-types in order to assess vaccine efficacy and population coverage in the ethnically diverse South African population. This descriptive study used web-accessible prediction servers to predict epitope binding of recently published putative epitopes for HCV vaccines against the South African HLA background. The main objectives of the study were:

1\) To characterise the variation of selected published immunogenic epitopes within popular target antigens, focusing on South African genotype 5a data.

2\) To predict the immunogenicity of these epitopes and their variants against the background of prevalent alleles in the South African target population.

Results
=======

Degree of conservation between epitopes
---------------------------------------

The Weblogo consensus was generated from individual alignments of all available sequence data of HCV genotypes (1a, 1b, 2, 3, 4, 5a and 6). Thus, seven web logos were generated for each of the 13 chosen class I- (N=6) and class II- (N=7) epitopes (Table [1](#T1){ref-type="table"}). The epitopes chosen for this study are well characterized and referenced (Table [1](#T1){ref-type="table"}). NS4B^2422-2433^ has only one reference (others have 22--78 references) but it is also the only one that has a different restriction allele i.e. B15. The HCV consensus was derived from the 7 generated weblogos and the percentage conservation within each genotype over the epitope region was calculated as described in the Methods (Table [2](#T2){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1).

###### 

Six well studied HLA class I- and seven class II- restricted HCV immunodominant epitope sequences were chosen from previous publications for this study

  **CLASS I EPITOPES**   **SEQUENCE (Subtype)**      **RESTRICTION**                    **REFERENCE**                    **NUMBER OF REFERENCES LISTED AT IEDB**
  ---------------------- --------------------------- ---------------------------------- -------------------------------- -----------------------------------------
  NS3 1073-1081          CINGVCWTV (1a)              A02                                \[[@B20],[@B21]\]                78
  NS3 1406-1415          KLVALGINAV (1a)             A02                                \[[@B22],[@B23]\]                70
  NS4 1807-1816          LLFNILGGWV (1a)             A02                                \[[@B24],[@B25]\]                39
  NS4 1851-1859          ILAGYGAGV (1)               A02                                \[[@B22]\]                       29
  NS5B 2422-2433         MSYSWTGALVTP (1)            B15                                \[[@B22]\]                       1
  NS5B 2727-2735         GLQDCTMLV (1)               A02                                \[[@B22]\]                       22
  **CLASS II**                                                                                                            
  Core 17-35\^           RRPQDVKFPGGGQIVGGVY (1)     Undetermined Class II allele       \[[@B26]\]                       1
  Core 21-40\^           DVKFPGGGQIVGGVYLLPRR (1)    HLA-DRB1\*1501                     \[[@B21],[@B26],[@B27]\]         13
  NS3 1248-1261          GYKVLVLNPSVAAT (1)          HLA-DRB1\*1201; 1101; 1301; 0401   \[[@B21],[@B25],[@B28]\]         5
  NS4A 1781-1800         LPGNPAIASLMAFTAAVTSP (1a)   Undetermined Class II allele       \[[@B25]\]                       3
  NS4A 1801-1820         LTTSQTLLFNILGGWVAAQL (1a)   Undetermined Class II allele       \[[@B25],[@B27],[@B29]\]         4
  NS5 2571-2590          KGGRKPARLIVFPDLGVRVC (1a)   Undetermined Class II allele       \[[@B4],[@B25],[@B27],[@B29]\]   4
  NS5 2661-2680          QCCDLDPQARVAIKSLTERL (1a)   Undetermined Class II allele       \[[@B27],[@B29]\]                4

\^Class II- restricted epitopes in the core region are overlapping sequences.

###### 

The sequences of the chosen epitopes were compared to the consensus sequence and conservation scores (as percentages) were calculated

  **CLASS I EPITOPE**    **Consensus Epitope sequence**   ***HCV GENOTYPES***   **Mean across genotypes**   **MAX.**   **MIN.**   **SD**   **p-value**                                                              
  ---------------------- -------------------------------- --------------------- --------------------------- ---------- ---------- -------- ------------- --------------------------- ---------- ---------- -------- -------------
  NS3^1073-1081^         CINGVMWTV                        78                    67                          67         67         78       67            70.67                       67         78         5.680    0.3062
  NS3^1406-1415^         LTSLGLNAV                        67                    56                          67         78         67       56            65.17                       56         78         8.280    0.1645
  NS4^1807-1816^         LLFNILGGW                        100                   78                          78         100        100      78            89.00                       78         100        12.049   0.6513
  NS4^1851-1859^         ILAGYGAGV                        89                    67                          89         78         89       67            79.83                       67         89         10.815   0.2231
  NS5B^2422-2433^        MSYSWTGAL                        89                    89                          89         100        89       67            87.17                       67         100        10.815   0.406
  NS5B^2727-2735^        GLRDCTMLV                        78                    56                          44         78         78       33            61.17                       33         78         19.823   0.4142
                         Mean within genotypes            83.50                 68.83                       72.33      83.50      83.50    61.33                                                                     
  **CLASS II EPITOPE**   **Consensus Epitope sequence**   **1**                 **2**                       **3**      **4**      **5**    **6**         **Mean across genotypes**   **MAX.**   **MIN.**   **SD**   **p-value**
  CORE^17-40^            RRPQDVKFPGGGQIVGGVYLLPRR         100                   96                          66         96         96       96            91.67                       67         78         5.680    0.3062
  NS3^1248-1261^         GYKVLVLNPSVAAT                   100                   93                          93         100        100      93            96.50                       93         100        3.834    0.32
  NS3^1781-1800^         LPGNPAVASLMATAAVTSP              85                    80                          95         85         90       65            83.33                       65         95         10.327   0.4142
  NS4^1801-1820^         LTTSQTLLFNILGGWVASQL             85                    65                          80         90         85       70            79.17                       65         90         9.703    0.962
  NS5B^2571-2590^        KGGRKPALIVYPDLGVRVC              80                    80                          90         95         95       80            86.67                       80         95         7.527    0.2231
  NS5B^2661-2680^        QCCDLEPEARVAIKSLTERL             85                    55                          70         80         60       50            66.67                       50         85         14.023   0.4159
                         Mean within genotypes            89.17                 78.17                       82.33      91.00      87.67    75.67                                                                     

The comparative variability of the epitope sequences within and across the different genotypes is shown in Table [2](#T2){ref-type="table"}. Genotypes 2 and 6 have the lowest mean intra-genotype scores for both class I- and II- epitope sequences, indicating a greater variation among subtypes within these genotypes. There is only one subtype within genotype 5 so not surprisingly the epitope sequences, including our sequences, from subtype 5a are relatively conserved. Because a large proportion of sequences on the database belong to genotype 1a or 1b, the consensus sequences that were generated is mostly representative of genotype 1 sequences. Mean conservation scores of genotype 5 sequences are the same as that of genotype 1 for class I- (both had an average score of 83.5%) and similar for class II- (87.67% versus 89.17%, for genotypes 5 and 1, respectively for the class II epitopes). The intra-genotype variation was not statistically significant for any of the epitopes selected. Two class I- epitopes (NS4B^1807-1816^ and NS5B^2422-2433^) and four of the six class II-epitopes had the highest average conservation scores of more than 80% (Table [2](#T2){ref-type="table"}). Published class II-restricted epitopes were, in general, better conserved than the class I- epitopes, both within and across the genotypes (Table [2](#T2){ref-type="table"}).Some epitopes were well conserved (NS4B^1807-1816^ and NS5B^2422-2433^) while others (NS5B^2727-2735^ and NS5B^2661-2680^) were highly variable (Table [2](#T2){ref-type="table"}).

Most epitopes were identified using genotype 1a sequences, hence it follows that the epitope sequences had greater identity with genotype 1. Genotype 4 epitope sequences showed a consistently high degree of correspondence with the consensus but since this genotype was represented by the smallest data set, this may not be a true reflection of variation within the genotype. Genotype 6 showed the most variability, with a mean conservation score of 61.33% within this genotype, which is to be expected since this genotype is known to be highly variable (Table [2](#T2){ref-type="table"}).

Major HLA alleles
-----------------

The most common HLA-A, -B and --C alleles in the South African Black population are classified into supertypes as described by \[[@B30]\]. For example, and as seen in Table [3](#T3){ref-type="table"}, the A02 supertype includes the A\*02:01 and A\*68:02 alleles. The A\*30:01 allele belongs to the supertype A01A03. This study predicted binding to 13 HLA class I- alleles in 8 supertypes and 8 class II- HLA-DR alleles predominant in the South African population.

###### 

Binding affinity scores of published epitopes and their variants were determined by the IEDB prediction program to relevant supertypes in South Africa

  **Gene**           **Epitope sequence**   **Genotype of epitope**       **Class A- Alleles**   **Class B- Alleles**                                                                                                         
  ------------------ ---------------------- ------------------------- --- ---------------------- ---------------------- ---------- ------- ---------- ---------- ---------- -------- ------- ---------- ---------- ---------- -------
  **NS3 (A\*02)**    CINGVCWTV              1a                            17802                  *67*                   *61*       14908   15501      12611      23637      20927    25523   19827      13679      19257      23485
  1073-1081          CVNGVCWTV              1b                            16997                  *110*                  **20**     12228   13122      11766      21885      15696    13382   18288      12132      20367      23007
                     SISGVLWTV              2a variant                    18961                  **11**                 **16**     21483   11417      11417      22455      22186    29702   18590      15055      15691      20667
                     TVGGVMWTV              3a                            19940                  *64*                   **8**      12677   14750      9776       20729      21877    24623   16182      18054      26500      24303
                     AVNGVMWTV              4a variant                    17734                  **23**                 **14**     24001   4015^\#^   12036      10753      20258    20595   17093      12996      13641      18882
                     CINGVLWTV              5a                            15172                  **26**                 **39**     17548   13613      13865      23524      21854    15854   18628      11203      17516      21090
                     CINGVMWTL              5a variant                    17922                  *140*                  *101*      10449   14413      11435      18947      13165    11237   2239       13165      13572      19956
  **NS3 (A\*02)**    KLVALGINA              1a                            22719                  *273*                  15048      32261   1830       18800      24242      25216    37253   23529      20557      4839       19019
  1406-1415          KLSGLGLNA              1b                            19133                  *475*                  21824      33559   2557       13152      20740      27147    37083   23891      19220      8973       18099
                     QLTSLGLNA              4a                            20013                  7051                   15292      33674   12859      12517      26454      24440    37244   22168      26218      7165       19904
                     KLVALGINAV             1a                            37929                  *52*                   8564       39134   NO VALUE   31977      19547      42247    34339   NO VALUE   NO VALUE   NO VALUE   26021
                     LTGLGINAV              5a                            12100                  5692                   *304*      32426   10980      20519      21309      20981    33652   25012      21599      12577      26332
                     QLTGLGINA              5a variant                    22408                  6972                   7419       34672   13389      17488      26117      23541    36968   25569      22283      15466      20054
  **NS4B (A\*02)**   LLFNILGGW              1a, 1b, 4, 5a                 22942                  14359                  17095      18086   17906      9175       24903      19854    17154   956^\#^    962^\#^    5918       23118
  1807-1816          MFFNILGGWV             3a                            24613                  23482                  19706      *343*   15640      1707^\#^   21757      11817    8151    10769      1251       13832      26621
                     LLFNILGGWV             1a, 1b, 4, 5a                 32231                  **44**                 1159^\#^   38969   NO VALUE   19453      32445      40287    25767   NO VALUE   NO VALUE   NO VALUE   25868
  **NS4B (A\*02)**   ILAGYGAGV              1a, 1b, 5a                    20500                  **15**                 530^\#^    30882   15492      10120      11883      21134    37213   22934      20702      3735       20143
  1851-1859          ILAGYGTGV              5a variant                    20351                  **18**                 *193*      32028   17493      12563      11272      21994    36657   23555      20603      2196       19849
  **NS5B (B\*15)**   MSYSWTGAL              1a, 1b, 4                     12612                  1522                   **24**     2924    2372       5457       1530^\#^   **50**   8456    10166      523^\#^    *80*       16876
  2422-2433          MSYTWTGAL              5a                            12133                  2640                   **22**     8602    2141^\#^   7606       2515^\#^   *58*     9150    10680      787^\#^    *144*      17267
                     YTWTGALIT              5a variant                    15779                  3000                   13286      33166   13737      1561       18979      3920     27619   22480      17360      6553       18765
  **NS5B (A\*02)**   GLQDCTMLV              1a                            18371                  **8**                  5733       11972   13187      6275       20996      27015    35681   25282      22002      10687      17601
  2727-2735          KLQDCTMLV              1b                            17735                  **7**                  3878       6160    2071^\#^   9527       17308      26776    35038   23310      18296      3587       16634
                     KLRDCTLLV              5a                            19744                  **13**                 14912      15150   **10**     5150       2800       27145    36627   21481      20362      1720^\#^   18071
                     ALRDCTMLV              4a                            19976                  **19**                 4673       19836   **29**     9982       5384       26302    36740   24190      22343      1206^\#^   20027

\<50 IC~50~nm, bold, high affinity.

\>50 IC~50~nm, \<500 IC~50~nm, *italic, intermediate affinity*.

\>500 IC~50~nm, \#, poor affinity.

No value indicates server produced no binding score.

Epitope binding prediction
--------------------------

The predicted binding values of the published and "newly predicted" epitopes to prevalent local class I-alleles were generated using the IEDB, ANN prediction server (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}, respectively). Predicted binding values of the published epitopes to local HLA class II- alleles were generated using the prediction server Propred, Quantitative matrix (Table [5](#T5){ref-type="table"}).

###### 

Binding affinity scores of "newly predicted" epitopes and their variants were determined by the IEDB prediction program to relevant supertypes in South Africa

  **GENE**   **EPITOPE SEQUENCE**   **GENOTYPE OF EPITOPE**          **Class A- Alleles**   **Class B- Alleles**                                                                                               
  ---------- ---------------------- ---------------------------- --- ---------------------- ---------------------- -------- ------- -------- -------- ------- --------- ------- --------- --------- ---------- -------
  NS3        LTGPTPLLY              5a, 1b                           **15**                 23679                  24474    24873   4551     **5**    24599   6188      7688    *448*     **28**    1558^\#^   22842
             LHGPTPLLY              1a                               10396                  24884                  27469    21381   17350    **10**   26731   12561     6443    21175     9987      *442*      23420
             FLSTATQTF              5a                               *165*                  15329                  17845    3634    1663     1886     15839   **40**    17977   16320     4231      **8**      18662
             IVSTAAQTF              1a                               20409                  23323                  22013    4758    11756    5496     11246   *75*      13372   814^\#^   *425*     *55*       22273
             VLSTVTQSF              1b, 2a                           18550                  13712                  17004    4838    16940    5785     15666   988^\#^   29052   11492     1654      **26**     21745
             IVSTDTQSF              4a                               19885                  22289                  20020    12440   14943    5300     6080    *151*     8229    4394      973^\#^   **47**     24757
             TLAGPKGPV              5a, 6a                           23444                  2081^\#^               **13**   33957   16907    18949    6657    21854     39095   25027     22108     20499      22034
             TLASPRGPV              1b                               22044                  1451^\#^               **8**    32375   13790    18855    2453    21660     39379   25346     22237     6235       22501
             TLASSRGPV              2a                               22034                  857^\#^                **11**   29481   9965     20464    2095    19022     38571   24511     22225     3353       22267
             TLASAKHPA              3a                               21914                  *413*                  **49**   29038   10681    19694    16284   12935     39038   24637     21967     13015      23364
             TIASPKGPV              1a                               22885                  7397                   **7**    34010   15054    20663    7437    19533     38620   25493     22070     16303      24145
             SVIDCNSAV              5a                               21948                  **30**                 **9**    24435   8789     12923    1702    4571      35486   21627     21514     3381       25586
             SVTDCNTCV              1b                               21476                  *131*                  **24**   30991   15202    21169    19345   15846     19349   26045     22021     11521      22609
             SVIDCNVAV              1b, 2a, 6a                       21855                  **15**                 **6**    22019   7833     13308    3218    4376      31399   24317     21463     3412       24232
             SVIDCNTCV              1a                               22281                  **25**                 **13**   23478   14812    17452    17390   13879     20769   25334     21666     7032       23918
             SVIDCNTSV              4a                               22543                  **18**                 **9**    25166   10636    15522    3402    11164     17097   24124     20942     4646       24512
             ITYSTYGKF              1b, 5a, 2a, 2b, 1a, 4a           16829                  22979                  16133    *124*   9722     *352*    21954   6132      16141   *354*     **43**    **27**     20982
             LTYSTYGKF              3a                               14296                  22834                  13829    *263*   10036    *379*    22076   3345      11660   860^\#^   **41**    **31**     20046
             KVLVLNPSV              1a, 1b, 2a, 2b, 4a, 5a, 6a       23587                  **50**                 6303     27046   **21**   18669    14670   21450     31145   20648     8842      3129^\#^   18558
             RAKAPPPSW              5a, 1b, 2a, 6a                   25817                  25080                  27568    8387    *308*    25791    7172    18126     8580    **31**    **11**    596^\#^    22382
             RAQAPPPSW              1b, 3a, 1a                       24980                  24747                  27454    22992   6443     24136    6017    14212     3253    **38**    **8**     1675^\#^   17482
             KVWLAPPPSW             4a                               24000                  4927                   22172    26746   *170*    16220    18770   9620      39029   21580     20215     12296      20633
             LTSLGVNAV              5a                               5815                   3795                   **42**   33629   6533     20008    16663   13886     27357   24243     18277     3860^\#^   24767
             LTSLGLNAV              5a variant                       5305                   3082                   *64*     32917   6065     18186    16615   16431     29952   24579     19519     7004       23118

\<50 IC~50~nm, bold, high affinity.

\>50 IC~50~nm, \<500 IC~50~nm, *italic, intermediate affinity*.

\>500 IC~50~nm, \#, poor affinity.

###### 

Binding affinity scores (as percentages) of Class II published epitopes and their variants were determined by the ProPred prediction program to common DRB1\* alleles prevalent in the South African population

  ***Epitope:***             ***Sequence***                   ***HCV Genotype specificity***             ***DRB1\*0101***   ***\*0102***   ***\*0301***   ***\*0401***   ***\*0701***   ***\*1101***   ***\*1301***   ***\*1501***
  -------------------------- -------------------------------- ------------------------------------------ ------------------ -------------- -------------- -------------- -------------- -------------- -------------- --------------
  **Core**^**17--42**^       **RRPQDVKFPGGGQIVGGVYLLPRRGP**   **1, 2, 5 & 3**^**var**^**& 6**^**var**^                                                                                                                 
                             VYLLPRRGP                        1, 2, 4, 5, 6                              0.0%               0.0%           18.0%          0.0%           0.0%           16.0%          **48.0%**      18.0%
                             VGGVYLLPR                        1, 2, 4, 5, 6                              0.0%               0.0%           17.0%          0.0%           9.0%           9.0%           10.0%          20.0%
  **NS3**^**1248--1261**^    **GYKVLVLNPSVAAT**               **1, 2, 4, 5, 6**                                                                                                                                        
                             LVLNPSVAA                        1, 2, 3, 4, 5, 6                           **37.0%**          **54.0%**      **36.0%**      **47.0%**      **28.0%**      17.0%          **34.0%**      **39.0%**
                             YKVLVLNPS                        1, 2, 4, 5, 6                              5.0%               0.0%           0.0%           **30.0%**      9.0%           **31.0%**      **27.0%**      17.0%
  **NS4B**^**1781--1800**^   **LPGNPAIASLMAFTAAVTSP**         **1a, 4**^**var**^                                                                                                                                       
                             LPGNPAVAS                        2,3, 5, 6                                  0.0%               2.0%           0.0%           4.0%           0.0%           0.0%           9.0%           0.0%
                             LPGNPAIAS                        1, 4                                       0.0%               0.7%           15.0%          4.0%           0.0%           2.4%           0.0%           7.0%
                             IASLMAFTA                        1                                          7.0%               **23.0%**      0.0%           0.0%           4.0%           0.0%           14.0%          **21.0%**
  **NS4B**^**1801--1820**^   **LTTSQTLLFNILGGWVAAQL**         **1a, 1b**^**var**^**,**                                                                                                                                 
                             LFNILGGWV                        1, 4, 5                                    0.0%               0.0%           16.0%          0.0%           **24.0%**      0.0%           16.0%          **28.0%**
                             FNILGGWVA                        1, 4, 5                                    **47.0%**          **47.0%**      0.0%           2.0%           16.0%          **28.0%**      16.0%          **31.0%**
                             ILGGWVASQ                        4, 5                                       0.0%               0.0%           **28.0%**      0.0%           0.0%           2.4%           8.0%           0.0%
                             LGGWVASQI                        4, 5                                       0.0%               0.0%           0.0%           0.0%           **21.0%**      0.0%           13.0%          **21.0%**
  **NS5B**^**2571--2590**^   **KGGRKPARLIVFPDLGVRVC**         **1, 2**^**var**^**& 6**^**var**^                                                                                                                        
                             VFPDLGVRV                        1                                          0.0%               0.0%           **34.0%**      0.0%           0.0%           0.0%           0.0%           0.0%
                             VYPDLGVRV                        3, 5                                       0.0%               0.0%           **35.0%**      0.0%           14.0%          0.0%           0.0%           19.0%
                             IVYPDLGVR                        3, 5                                       0.0%               0.0%           **28.0%**      0.0%           0.0%           0.0%           7.0%           0.0%
                             LIVYPDLGV                        3, 5                                       0.0%               0.0%           0.0%           0.0%           12.0%          0.0%           3.0%           **60.0%**
  **NS5B**^**2661--2680**^   **QCCDLDPQARVAIKSLTERL**         **5**^**var**^                                                                                                                                           
                             LAPEARQAI                        1b                                         0.0%               0.0%           8.0%           0.0%           11.0%          0.0%           4.5%           11.0%
                             LDPQARVAI                        5                                          0.0%               0.0%           8.0%           0.0%           0.0%           0.0%           0.0%           0.0%
                             LQPEARAAI                        5^var^                                     0.0%               0.0%           **22.0%**      0.0%           12.0%          1.0%           **22.0%**      **26.0%**

### HLA-A and --B class I- restricted binding

Binding predictions of epitopes and their variants for all available HLA alleles prevalent in the South African population are shown in Table [3](#T3){ref-type="table"}.Five of the six HLA class I-published epitopes (NS3^1073-1081^, NS3^1406-1415^, NS4B^1807-1816^, NS4B^1851-1859^ and NS5B^2727-2735^) have been reported to be HLA-A\*02 restricted (Table [1](#T1){ref-type="table"}). Three of the five published HLA-A\*02 restricted epitopes bound the A\*02:01 allele as expected (Table [3](#T3){ref-type="table"}).

Predictions for the different alleles were in agreement regardless of the programme or algorithm used (IEDB ANN, Propred I, SYFPEITHI) with two exceptions, binding of the 9 amino acid epitopes of NS4B^1807-1816^ LLFNILGGWV and the HLA-B\*27:05 binding predictions. The original 10 amino acid NS4B^1807-1816^genotype 1 epitope LLFNILGGWV (which is conserved in genotype 1b, 4 and 5a) predicted to bind with high affinity (44.1 IC~50~nM) to HLA-A\*02:01. Neither IEDB ANN nor ProPred I predicted binding between this allele and the two possible 9 mer epitopes, LLFNILGGW and LFNILGGWV while SYFPEITHI predicted binding of 18% and 14%, respectively. One of the shortcomings of IEDB ANN is that it can only predict binding peptides that are of the same length as those in the training set. For this reason, all peptides were re-analysed with all the alleles of interest using the "any length" parameter for epitope length. No other changes were observed to binding predictions listed in Table [3](#T3){ref-type="table"} using these parameters.

The second exception observed was the failure of IEDB ANN to predict binding between any of the epitopes (or their variants) and HLA-B\*27:05 which SYFPEITHI and/or ProPred I scored. There was no data supporting restriction of these particular peptides by B\*27:05 in the IEDB epitopes database. Both SYFPEITHI and ProPred I use peptide motifs and amino acid matrix based prediction. The following scores using x-\[R (K)\]-x ^(6--9)^ could explain the scoring of these two packages for NS3^1406-1415^epitopes [K]{.ul}LVALGINA, [K]{.ul}LSGLGINA (21%^ProPredI^ 7%^SYFPEITHI^, respectively) and variants [K]{.ul}LQDCTMLV and [K]{.ul}LRDCTLLV (32%^ProPredI^ 12%^SYFPEITHI^, respectively). SYFPEITHI uses x-\[R\]-x ^(5--8)^-\[LFYRHK (MI)\]. However, one would expect lower predictions for NS5B^2422-2433^ epitopes MSYSWTGA[L]{.ul} and MSYTWTGA[L]{.ul} (38%^ProPredI^ 12%^SYFPEITHI^) since only the carboxyl anchor is present but this was not the case.

NS3^1073-1081^, NS4B^1851-1859^ and NS5B^2727-2735^ bound with high affinity to A\*02:01 allele, regardless of genotypic variation (Table [3](#T3){ref-type="table"}). All variants tested for both NS5B^2727-2735^and NS4B^1851-1859^ were predicted to bind the A\*02:01 allele with equal strength (\<20 IC~50~nM, Table [3](#T3){ref-type="table"}). High and intermediate binding affinities over all variants was also observed for NS3^1073-1081^ and NS4B^1851-1859^ with allele A\*68:02 (Table [3](#T3){ref-type="table"}), of the A02 supertype.

Two of the variants, SI[S]{.ul}GVLWTV (genotype 2a) and TV[G]{.ul}GVMWTV (genotype 3a) had changes from the wild type N (Asparagine) in position 3 but none of the variants had changes in positions 4, 5 and 7. Interestingly, when all possible alanine exchange peptides were placed into IEDB ANN, the output scores reflected the experimental binding changes for all of the alanine exchange peptides with the exception of the total abrogation of signal for substitutions in positions 3, 4 and 5 (data not shown).Of note, while consistent binding was observed across the supertype A02 for all of the variants of the A\*02 restricted epitope NS3^1073-1081^, epitopes of genotypes 1, 3a and 5a (variant) were found to be intermediate binders (Table [3](#T3){ref-type="table"}).

The genotype 4a and 5a variants of the HLA-A\*02 restricted epitope NS5B^2727-2735^displayed some level of promiscuity as these were predicted to bind with high affinity to the A01A03 supertype allele, A\*30:01 (29 and 10 IC~50~nM, respectively), while the genotype 1b variant had low affinity with this allele (2071 IC~50~nM) and the original genotype 1a peptide was not predicted to bind at all. The original peptide and one of the two of three variants of the published B\*15-restricted NS5B^2422-2433^ epitope displayed intermediate binding IC~50~ nM values of 80 and 144 (Table [3](#T3){ref-type="table"}). This epitope showed the highest cross-reactivity across the supertypes with both the original epitope and one of the genotype 5a variants binding very strongly to A\*68:02 (supertype A02) and B\*35:01 (B7 supertype; Table [3](#T3){ref-type="table"}).

Of the 6 class I- epitopes used in this study, only two epitope variants were found to be promiscuous: MSYTWTGAL (supertypes A02, B07, B27) and KLRDCTLLV (A02, A01A03).In a preliminary attempt to identify conserved epitopes showing greater promiscuity across supertypes, strings of epitopes (other than the ones selected from publications for this study) of the NS3 protein were placed into the IEDB server. Table [4](#T4){ref-type="table"} indicates that five of the eight epitopes were predicted to be promiscuous, binding with high (\<50 IC~50~nm) and intermediate (\<500 IC~50~nm) affinities to two or more supertypes: LTGPTPLLY (A01, A01A24, B58), FLSTATQTF (A01, B07, B58, B27), ITYSTYGKF (A24, A01A24, B58, B27), KVLVLNPSV (A02, A01A03), RAKAPPPSW (A01A03, B58). Of the five epitopes above, three were conserved among genotypes 1, 2, 4 and 5 (Table [4](#T4){ref-type="table"}), ITYSTYGKF, KVLVLNPSV and RAKAPPPSW.

### Class II- alleles

ProPred II was used to predict binding of the longer class II- epitopes. Before calculating the predicted binding, the programme identifies all overlapping nine amino acid peptides within the input polypeptide. A predicted binding score is given as a percentage of the maximum possible binding (i.e. the highest log value achievable by an optimal peptide) with the chosen allele (Table [5](#T5){ref-type="table"}). For example, CORE^17-42^, RRPQDVKFPGGGQIVGGVYLLPRRGP, returned two 9-mer peptides, VYLLPRRGP and VGGVYLLPR, which scored similarly for alleles HLA-DRB1\*03:01 and HLA-DRB1\*15:01 (Table [5](#T5){ref-type="table"}). However, in the context of DRB1\*13:01, VYLLPRRGP had a much higher percentage binding score (48%) than its flanking sequence VGGVYLLPR (10%). Note that no class II- epitopes were predicted in the first 14 amino acids of CORE^17-42^. The CORE^17-42^ epitope was well conserved across the genotypes (second only to NS3^1248-1261^, Table [2](#T2){ref-type="table"}), but was not predicted to bind with HLA-DRB1\*01:01, HLA-DRB1\*01:02 or HLA-DRB1\*04:01 and only VGGVYLLPR was predicted to bind with HLA-DRB1\*07:01 (9%, Table [5](#T5){ref-type="table"}).

The most promiscuous class II-epitope was also the best conserved epitope, NS3^1248-1261^(Table [2](#T2){ref-type="table"}), specifically the region 1252--1260 LVLNPSVAA, bound all eight of the alleles tested and was the only epitope to bind HLA-DRB1\*04:01.The allele HLA-DRB1\*15:01 was predicted to bind with all but five of the 18 peptides output by the program (Table [5](#T5){ref-type="table"}). The highest percentage of optimal binding (60%) was predicted between peptide LIVYPDLGV within NS5B^2571-2590^ and the HLA-DRB1\*15:01 allele.This immunogenic epitope is one of three variants common to genotypes 3 and 5.

The NS3^1248-1261^ epitope YKVLVLNPS was well conserved among genotypes and bound to three DRB1\* alleles (Table [5](#T5){ref-type="table"}). Interestingly, the epitope KVLVLNPSV, also conserved, bound to two class I- supertypes (Table [4](#T4){ref-type="table"}). Another epitope that is a class I- and II- binder is FNILGGWVA (Table [3](#T3){ref-type="table"} and Table [5](#T5){ref-type="table"}, respectively).

### Coverage calculations

The predicted binding scores of published epitopes (Tables [3](#T3){ref-type="table"} and [5](#T5){ref-type="table"}) were used to estimate population coverage. Selected programme output (which includes a list of the input epitopes) has been supplied as supplementary figures where indicated.

#### IEDB population coverage

The published class I- and II- epitopes had coverage of 65.85% (Additional file [2](#S2){ref-type="supplementary-material"}: Figure S2) in South African Blacks and 81.36% (Additional file [3](#S3){ref-type="supplementary-material"}: Figure S3) in South African Whites. Corresponding figures when calculations included only the class I- epitopes were 41.76% and 52.70%, respectively (results not shown). By choosing predominantly genotypes 1 and 5a epitopes ("best mix") predicted to be immunogenic in South African Blacks, the combined class I- and II-coverage in Blacks improved to 91.87% (Additional file [4](#S4){ref-type="supplementary-material"}: Figure S4) while coverage improved to 94.77% (Additional file [5](#S5){ref-type="supplementary-material"}: Figure S5) in the South African Whites.

#### Optitope Population Coverage

The Optitope candidate epitopes were proposed whether the chosen population was "North American Europeans" or Europe (geographical) and results showed coverage of 94.28% (Additional file [6](#S6){ref-type="supplementary-material"}: Figure S6). Alternatively, candidate epitopes were sought using the same HCV alignment data and choosing the Zulu ethnic group (the only South African ethnic group available in OptiTope) and coverage of 75.16% was shown (Additional file [7](#S7){ref-type="supplementary-material"}: Figure S7).

#### Optitope Epitopes and IEDB population coverage

Candidate epitopes chosen for "optimal" vaccines for Caucasians and Zulus, respectively, from the OptiTope analyses described above, were then tested using the South African white and black populations. Local population data was placed into the IEDB population coverage web application as before.

Results indicated that South African Blacks had a 72.64% chance of responding to a putative European "optimal" vaccine while the same vaccine provided 90.55% coverage in the population for which it was designed. The putative "optimal" vaccine for Zulus provided coverage of 73.72% in South African Blacks with 90.79% coverage in Europeans (summarized in Additional file [8](#S8){ref-type="supplementary-material"}: Figure S8).

Discussion
==========

HCV genotypes and host genetics vary geographically and yet proposed epitope vaccines are most often formulated based on genotype 1 peptide sequence data alone and their restriction confined to the alleles found predominantly in the Caucasian population. This study assesses the efficacy of a putative epitope vaccine designed with this typical sequence bias when used in South African populations. The heterogeneity of epitope regions proposed for HCV vaccines was explored together with their predicted binding, and that of their variants, to HLA alleles common in the South Africa population.

There is a need to examine viral variation within known epitopes, and assess the prevalence and immunogenicity of the variants for relevant host alleles within the target population, before choosing epitopes for inclusion in an epitope vaccine. This study, therefore, focused on subtype 1a, 1b and 5a sequences as these were found to predominate in South Africa \[[@B15]\]. This is the first time that South African genotype 5a data is being compared to well- studied epitope data of other genotypes. Genotypes 3 and 4 have also been found in the South African population but genotype 2 is rare and, to date, genotype 6 has not been identified. In order to improve the representation of genotype 5a, all available sequence data was included in the alignments, including sequences from our own studies and those of \[[@B31]\] (Belgium and South Africa) and \[[@B32]\] (France).

There are numerous epitopes meeting the inclusion criteria that could have been chosen for the study but a final subset was chosen so that it included well studied epitopes considered for multi-epitopic \[[@B22]\], therapeutic \[[@B21]\], minigene \[[@B25]\] and DNA polytope \[[@B23]\] vaccines.Genotype 1 is a well-studied genotype and considerably more sequences were available for the genotype 1 alignments. Class I- and II- epitope sequences of genotype 5a were found to be relatively conserved compared to some of the other genotypes, notably genotypes 2, 3 and 6.Genotype 5 is considered to be a relatively conserved genotype as to date, there is only one subtype of genotype 5 (5a), compared to the highly intra-genotypically variable genotype 6 that partitions into 22 different subtypes, 6a-6v, considerably more than any of the other genotypes \[[@B33]\].

There have been several studies which show a lack of cross-protection across the genotypes \[[@B34]-[@B36]\]. With regard to the NS3^1073-1081^epitope, an extensively studied epitope, our study has predicted high and intermediate binding of variant sequences to A02 supertype, indicating a level of cross-reactivity for this epitope. The consensus at the position 2 of NS3^1073-1081^ was an isoleucine (I). The only other common amino acid in this anchor position was Valine (V). Valine was conserved at position 9 in all but the genotype 5a sequences where approximately one third of the sequences had a leucine (L) in this position. Despite the fact that substitutions at P2 were conservative (an I or V for the more favourable L), affinity of this epitope was lowered. When alanine exchange peptides were used in *in vitro* assays \[[@B37]\], substitutions at positions 3, 4, 5 and 7 of the published NS3^1073-1081^ epitope abolished IFN-gamma production. Changes at positions 2, 8 and 9 only partially reduced production and only positions 1 and 6 had no effect. Even single amino acid exchanges at non-anchor sites can significantly limit the potential efficacy of a vaccine containing only the wild type peptide \[[@B37]\].

\[[@B36]\] identified distinct polymorphism profiles of genotypes 1a and 3a non-structural gene sequences. Only 2 of the 51 polymorphisms, observed to have significant HLA association, were common to both genotypes \[[@B36]\]. The extent of genetic diversity can result in a distinct repertoire of HLA-restricted viral epitopes for different genotypes. When we looked at consensus alignments of the chosen epitopes, we also observed this phenomenon. The consensus at each site of an epitope represents the amino acid best adapted to T cell responses across the host population \[[@B36]\]. A consequence of this is that escape of a mutant (driven by the selection pressure of dominant HLA alleles within the host population) can become the most dominant amino acid. When this happens, the polymorphism in the epitope, or negatope, as it is now called, is over-represented even in hosts not having the allele which drove the escape \[[@B36]\].

One of the shortcomings of IEDB ANN is that it can only predict binding peptides that are of the same length as those in the training set. Hence, the server will not pick up binding in longer epitopes if this is not specified \[[@B38]\]. However, by using older programs, such as SYFPEITHI and BIMAS that use peptide motifs and amino acid matrix based prediction (\[[@B39]\]; Singh and Raghava 200) both of which are popular, updated and have relevance \[[@B40]\] we were able to flag the longer epitopes and repeat the prediction in IEDB ANN for the 10 amino acid epitope.

Epitopes which are well conserved and show good binding affinities to many HLA alleles (promiscuous) are the best candidates for *in vitro* and/or *in vivo* testing. Epitopes like NS4B^1801-1820^are particularly appealing since they contain substrings which act as class I- and class II- alleles. While *in silico* planning has been found to greatly facilitate peptide design, not all peptides predicted *in silico* are optimally immunogenic *in vivo*\[[@B41]\] and it remains essential to test predicted peptides *in vivo* so as to ascertain that the needed T-cell response is elicited. Numerous *in silico* studies have shown the value of using prediction programs to assess the efficiency of binding of putative epitopes to human alleles \[[@B42]-[@B45]\]. Also, \[[@B46]\] showed an increase in the use of *in silico* prediction studies with an improvement of epitope prediction programs available. Of the published epitopes used in this study, only 2 class I- (based on binding to ≥supertypes) and 3 class II- (binding to \>2 DRB1\* alleles) epitopes were found to be promiscuous using the prediction programs.

The NS3 protein is a large protein and has been shown to generate effective immune responses, which can resolve acute infection. This study looked across the NS3 protein to identify possible additional epitopes (other than the ones chosen from the published papers) that may be good binders to predominant HLA-alleles in the South African population. The results of this search (Table [4](#T4){ref-type="table"}) which we have called, "newly predicted" NS3 epitopes were found to be well-conserved and bind to more than one HLA class I- allele. Three class I- epitope sequences were found to be highly conserved, particularly among genotypes 1 and 5, and were predicted to be strong binders to two or more supertypes. None of these "newly predicted" NS3 epitopes were found on the Los Alamos HCV immunology database (<http://hcv.lanl.gov/content/immuno/tables/ctl_summary.html>, accessed 05-09-2012). This exercise illustrates the usefulness of *in silico* studies to identify potential binders which will suit the target populations. *In vivo* studies will always be needed to confirm immunogenicity of these predicted peptides but this study has shown that *in silico* prediction can consider both host and viral variation, particularly in countries like South Africa and Egypt where genotypes other than genotype 1 predominate. *In silico* coverage calculations can not only identify promiscuous epitopes but also optimise the best cocktail for an effective multi-epitope vaccine. A recent *in silico* study identified 69 promiscuous HCV class I- and 150 class II- epitopes that were predicted to bind to genotype 3a \[[@B44]\]. A string of 18 conserved and promiscuous immunodominant epitopes spanning 8 HIV-1 proteins produced an effective immunogen \[[@B47]\], 23 epitopes were found promiscuous to MHC class I- and II- within *E-coli* 536 genome \[[@B45]\] and 15 promiscuous epitopes were predicted within *M. tuberculosis* peptide \[[@B43]\].

This study focused mainly on A02 --restricted epitopes and promiscuity was poor. However, immunogenic epitopes restricted to other alleles have been identified \[[@B48]-[@B50]\]. Two B alleles, B57 and B27, have been found to provide spontaneous control of HCV. Neither of these alleles are prevalent in South African Blacks (Paximadis et al., 2011) but preliminary investigations on NS5B (B\*57-restricted) epitope, KSKKTPMGF (genotype 1a, \[[@B48]\]), and genotype 5a variants RSKKTPMAF and KSKKIPMAF showed promiscuity to B\*58:01, B\*15:03 and A\*30:01(data not shown). Indeed, this reiterates the need to look at viral variation and promiscuity as this is particularly important to vaccine design.

The following class I- and II-restricted epitopes were selected from the original epitope set as likely to provide the best vaccine in the South African setting. This was based on binding affinities predicted for epitopes expected in the local population and binding to several supertypes recently recommended for inclusion in a vaccine which is optimal for both White and Black South Africans (supertypes A1, A2, B07, B27 and B58; \[[@B13]\]).

1\. NS3^1073-1081^ both wild type genotype 1a CINGVCWTV and genotype 1b CVNGVCWTV because they are so well studied and show cross-reactivity within variants and across the supertype A02.

2\. NS4B^1807-1816^ (LLFNILGGWV; \[[@B22],[@B24],[@B25]\]) because the 10-mer peptide is well conserved (genotypes 1a, 1b, 4, 5a) and is immunogenic for both class I- and class II- alleles.

3\. NS5B^2422-2433^, both the original MSYSWTGAL (genotypes 1a, 1b and 4; Table [3](#T3){ref-type="table"}; \[[@B22]\]) and the genotype 5a variant MSYTWTGAL as they cover the supertypes B27 as well as B07 and are also the best available B58 candidate in the recommended supertype set \[[@B13]\].

4\. NS5B^2727-2735^genotype 5a variant KLRDCTLLV of the published epitope sequence GLQDCTMLV \[[@B22]\] as it brings the most prevalent HLA-A allele in the Black population (A\*30:01) and the most prevalent HCV genotype 5a in South Africa into the mix.

5\. The class II-restricted epitopes NS3^1252-1260^ LVLNPSVAA \[[@B27]\] which is conserved in all genotypes and also very promiscuous.

6\. NS4B^1809-1817^ which overlaps class I-restricted 1807 (FNILGGWVA; \[[@B25]\]) and is restricted by the 2 HLA-DR alleles in the Black population (HLA DRB1\*13:01 and \*11:01) and is also promiscuous.

7\. Core class II- epitope VYLLPRRGP (genotypes 1,2,4,5,6) included as it is the most reactive of the class II- epitopes to HLA DRB1\*13:01.

The frequencies of the most common HLA alleles in the South African Caucasian and Indian populations closely correlate with values from their respective populations globally. However, the frequencies of the most common HLA-A and --B alleles in the South African Black population are both heterogeneous and unique and quite distinct even from other Black populations in Western and Northern Africa \[[@B51]\]. Many of the well studied published and "newly predicted" epitopes assessed in this study bound to A\*68:02 (supertype A02). HLA-A\*68:02 was found 2.6x more often in the Black population than HLA-A\*68:01 (A03 supertype, \[[@B13]\]).

There is a good correlation between immunogenicity and MHC class I- binding affinity \[[@B52]\]. Based on this principle, several web-based resources are available which can assess the population coverage of putative epitope vaccines based on the predicted binding of the epitopes and their variants to chosen HLA alleles relevant to the population being assessed. The predicted coverage of the original well studied class I- and II-epitopes selected for this study to illustrate the drawbacks of a vaccine using South African host population frequencies was found to be 65.85% and 81.36% for Blacks and Whites, respectively (Additional file [8](#S8){ref-type="supplementary-material"}: Figure S8).The OptiTope example highlighted the fact that the greater the knowledge of local viral variation and the immunogenicity of these variants together with accurate high resolution population allele frequencies allows the design of superior epitope vaccines with much better coverage for more groups within the target population. Fine tuning the vaccine by using an optimal cocktail of genotype 1 and 5a epitopes raised the coverage of the vaccine to 91.87% and 94.77%, close to the 100% coverage predicted by \[[@B13]\] in their study population.

Conclusion
==========

In light of data generated in this study, epitope-based HCV vaccines should contain a mixture of epitope variants from all of the genotypes as wild-type genotype 1 response is not guaranteed to cross-protect against variants, even if the variant is restricted by the same allele. In addition the efficacy of a proposed epitope vaccine will differ between the major population groups. While coverage estimates can be made based on South African supertypes, cross-reaction of peptides with all supertype members is not universal. Clearly for a set of epitopes to elicit a broad and potent immune response in the target population, viral variation and population genetics data should be factored into the algorithm particularly in the light of less-studied variants such a genotype 5a.

Even where proposed epitopes are conserved, host differences will make the vaccine less effective in the South African setting. Of the 13 published and well-characterised epitopes selected for this analysis (including variants from two of these) four class I- and three class II-restricted epitopes would be beneficial in a multi-topic therapeutic vaccine for genotype 5a infection in our population. Hepatitis C genotypes and high resolution population data is necessary when planning epitope vaccine design. While *in vivo* and *in vitro* studies are needed to confirm predicted immunogenic epitopes, *in silico* "reverse immunology" studies provide a sound basis with which to screen the many possible candidates. This study has shown that with the ease and usefulness of web-based sequence- and structure-based prediction servers, non-bioinformaticians can predict potential binders, without expensive computer hardware and programming knowledge.

Methods
=======

Epitope sequences
-----------------

The literature was searched for known immunogenic class I- and II-restricted epitope vaccine candidates. All of the open reading frames (ORF), from the core to the NS5B protein, yielded putative epitopes and these ranged in length from 9 base pairs (bp; \[[@B22]\]) to 683 bp \[[@B53]\]. Six class I- and seven class II- epitopes were chosen for the analyses (Table [1](#T1){ref-type="table"}) based on the following criteria:

1\. All were extensively studied immunogenic epitopes (as indicated by the number of references in Table [1](#T1){ref-type="table"}).

2\. All had been published in the peer reviewed literature.

3\. All class I- epitopes had known HLA restriction.

4\. All had been recommended for putative vaccines.

5\. All were from conserved regions of the genome (core to NS5 region).

Alignments of representative reference sequences were obtained over the chosen putative epitope regions using sequence data from each of the genotypes with the aid of pre-aligned and updated amino acid sequence data from the International Nucleotide Sequence Database Collaboration (INSDC; \[[@B54]\]).

The total number of sequences, available per epitope region, varied in numbers by genotype and region on the genome. Genotype 1 (subtypes 1a and 1b) sequences form by far the major number of sequences on the database ranging from 54% (of the total number of sequences) to 84% in some regions. In contrast, the little studied genotypes, genotype 4 and 5, accounted for only 4 to 24% of available sequences, respectively. Genotype 5a is one of the major genotypes found in South Africa together with genotype 1. Thus, to have this local type adequately represented in the data set, we included our own sequence data (25 patients) from the core \[GenBank:JX571010-JX571031\], NS4B \[GenBank: JX571032-JX571039\] and NS5B \[GenBank: DQ482799-DQ482824\] regions of genotype 5a.Care was taken to ensure that all our own data, as well as data used from public databases, corresponded to one sequence per subject. The study was retrospective and approved by the ethics committee of the University of the Witwatersrand, Johannesburg, South Africa (WITS HREC M051114), and was therefore performed in accordance with the ethical standards of the 1964 Declaration of Helsinki. PCR and sequencing was performed as previously described \[[@B15],[@B31]\].

BioEdit (version 7.0; \[[@B55]\]), was used to align all the amino acid sequences. The consensus sequence of immunogenic regions, for each of the genotypes, was generated using the Web based software package, WebLogo (version 2.8.2; <http://weblogo.berkeley.edu/logo.cg>; 2008-09-08). Sequence numbering is according to \[[@B56]\]. WebLogo produces a consensus of the input sequences output as a series of "letter stacks", each representing a single column of the sequence alignment (Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1).The height of each letter within the stack is proportional to the relative frequency of the representative amino acid at that position in the sequence \[[@B57]\]. The Weblogo software incorporates a "small sample number" correction, to correct for potential bias.

The relative conservation of each epitope was calculated as a percentage of the number of polymorphic sites over the epitope length when compared to the overall HCV consensus sequence. The HCV consensus was determined by taking the most common amino acid at each amino acid site of the 7 respective genotype consensus sequences (genotypes 1a, 1b, 2, 3, 4, 5a and 6), irrespective of representation in the database. A minimal class I-restricted epitope length of 9 nucleotides was used for all class I-restricted epitopes. Since class II-restricted epitopes are longer and are made up of numerous overlapping regions, the number of amino acids per epitope varied. The statistical analysis was performed using the analysis of variance (ANOVA) tests of significance in the Statistica software, version 9.1.

Common South African HLA alleles
--------------------------------

Initially, a literature search was conducted in order to collate available South Africa population HLA-A --B and --DR allele frequency data which included relevant data stored online in the New allele Frequency Database (<http://www.allelefrequencies.net> 2010-11-30). However, much of this data was low resolution with 2 digits. Hence, high resolution data \[[@B13]\], which is required for the predictions, were used for the study.

Immunogenicity prediction and population coverage calculations
--------------------------------------------------------------

Two servers (Immune Epitope Database, IEDB (<http://tools.immuneepitope.org>, \[[@B58]\]) and Propred II, <http://www.imtech.res.in/raghava/propred/index.html>, \[[@B59]\]) were chosen for this study because these were user-friendly, easily available online and displayed many of the HLA alleles prevalent in SA. To predict binding to HLA class1- alleles, the IEDB server was used. The Propred II server was used to predict binding to HLA class II- alleles.

### Resources of the immune epitope database (IEDB)

The IEDB is a manually curated database of experimentally characterized immune epitopes. Its companion site, the IEDB resource, is a collection of tools for prediction and analysis of immune epitopes (<http://tools.immuneepitope.org/main/jsp/menu.jsp>; version 2.0, accessed 2009-09-09 to 2011-03-14, \[[@B60]\]). The "Peptide Binding to MHC class I- molecules" resource, which predicts MHC binding to T cell epitopes, was utilised for class I- predictions. Valid input data include proteins or peptides. The programme splits these into all possible overlapping peptides and then predicts their binding to each selected MHC allele using the chosen prediction method. The sequence-based method, using the artificial neural network (ANN) algorithm of \[[@B61]\] on the IEDB server was selected for all HLA class I-predictions as it is reported to be more reliable than earlier matrix algorithms \[[@B61]\].

In addition, however, the matrix-based methods, ProPred 1 (<http://www.imtech.res.in/raghava/propredI/index.html>, 2010-11-30, \[[@B62]\]) and SYFPEITHI \[[@B39]\] were used in parallel and binding efficiencies of the three methods compared. For brevity, only scores for IEDB are shown in the result tables and incompatible results are discussed where appropriate. ANN uses training data from the IEDB to calculate the affinity of a given peptide for specific MHC molecules. It calculates binding based on the position of each amino acid in the putative epitope while taking into account the probability of adjacent amino acids competing for a space in the MHC pocket. Predicted binding efficiencies are calculated in units of IC~50~nM (the half-maximal inhibitory concentration). IC~50~ values \<50 nM indicate high affinity while values \>500 but \<5000 nM indicate low affinity and values in between the two extremes (\>50 nM but \<500 nM) indicate intermediate affinity (<http://tools.immuneepitope.org/main/jsp/menu.jsp>).

Sequence data in the NS3 region that was available on the database was used for the genotype 5 conservation score and binding to predominant HLA-alleles in the South African context were predicted.The promiscuity of "newly predicted" (i.e. other than published epitopes) class I-epitopes of the NS3 gene were analysed using the IEDB server. An epitope sequence that bound with \<500 IC~50~nM to more than one HLA class I- allele was considered promiscuous.

### ProPred MHC class II- binding prediction

A structure-based method with a quantitative matrix (QM) algorithm on the Propred II server (<http://www.imtech.res.in/raghava/propred/index.html>, 2010-10-20, \[[@B63]\]) was used to predict binding of HLA class II- epitopes. This tool uses a linear prediction model which scores the binding potential of the query peptide based on values stored in allele specific coefficient tables, or quantitative matrices. Matrices are generated based on experimental results taking into account the properties of each individual amino acid and its position within the epitope.

The program is useful in locating promiscuous, versus allele specific, binding regions in a query peptide sequence. Note that, by comparison to IEDB ANN, a high score is indicative of good binding between the relevant peptide and the specific HLA allele and vice versa. The score represents the percentage binding of the query peptide when compared to the highest possible binding score for the optimal peptide with the given allele and thus reflects the binding characteristics of the query peptide. However, there is no clear cut off as with IEDB ANN scoring, and actual percentages should not be compared between alleles. The stringency threshold of the analysis can be set between 1% and 10% where the highest stringency guarantees no false positives and the lowest stringency guarantees no false negatives. The highest stringency was, therefore, used in all programme runs to minimize the number of false positives and ensure that all binding had significance.

### Population coverage calculations

Population coverage was calculated by the Population coverage tool on the IEDB server (<http://tools.immuneepitope.org/tools/population/iedb>) for South African Whites and Blacks for both the published class I- and II- epitopes and an adapted "best mix" which took into account the most prevalent alleles and epitope variants in South Africa and their predicted binding. In order to assess the efficacy of a vaccine epitope, the IEDB resource Tool calculates the fraction of individuals predicted to respond to a given set of epitopes with known MHC restrictions (<http://tools.immuneepitope.org/main/html/analysis_tools.html> last accessed 2011-04-20). The calculation is based on input HLA genotypic frequencies.

Recently released web-based software, OptiTope \[[@B64]\], looks at viral and host variation in order to customise and optimise candidate epitopes to a specific population. Since this approach used the same parameters as this study, it was decided to compare the coverage of the chosen epitopes with the coverage of putative optimal epitope vaccines generated in OptiTope using similar biases. For this reason OptiTope was asked to generate an optimal epitope vaccine from an alignment of "common" HCV sequences in a Caucasian population. This HCV sample data (available in OptiTope), while biased, was very comprehensive and consisted of an alignment of \>100 sequences from 10 different HCV proteins (Core, E1, E2, NS2, NS3, NS4A, NS4B, NS5A, NS5B and p7) but only included the "common" subtypes 1a, 1b, 2a and 3a.
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###### Additional file 1

**Figure S1.**An example of consensus Weblogos alignments for the NS3^1406-1415^ peptide for each of the 7 subtypes/genotypes studied. Percentage correspondence with the HCV consensus epitope 1407--1415. Average conservation was 65.17% (p = 0.1645), also shown in Table [2](#T2){ref-type="table"}.
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###### Additional file 2

**Figure S2.**Epitope and population coverage in South African Blacks with original published epitopes, using IEDB.
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###### Additional file 3

**Figure S3.**Epitope and population coverage in South African Whites with original published epitopes, using IEDB.

###### 

Click here for file

###### Additional file 4

**Figure S4.**Epitope and population coverage in South African Blacks with "best mix", using IEDB.
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###### Additional file 5

**Figure S5.**Epitope and population coverage in South African Whites with "best mix", using IEDB.
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###### Additional file 6

**Figure S6.**Epitope and population coverage in Caucasians (North American and Europe), using OptiTope.
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###### Additional file 7

**Figure S7.**Epitope and population coverage in Zulus (South Africa), using OptiTope.
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###### Additional file 8

**Figure S8.**A summary of the steps and results of the population coverage analyses, using the IEDB and OptiTope.
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